Cardiac stem cell therapy for regenerating diseased heart tissue has been long on promise but short on delivery. A Belgian incubator and start-up hope to finally bring this treatment to market.
By Stephen Levin
Whenever the subject of future technologies for treating cardiovascular disease comes up, both industry executives and clinicians agree that emerging...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.
Early commercial successes are proving the value of digital twins, yet regulatory uncertainty and cultural resistance continue to limit widespread uptake across biopharma.
The gap between investor returns and patient returns is precisely that which the SALY/SADY framework is designed to fill.
Charles River's chief scientific officer Julie Frearson discusses how the agency's embrace of artificial intelligence is driving a fundamental shift in how companies must structure and manage their research data
The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.
An interactive look at pharma, medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.
